Plain-English translation of NCT07407790 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a stroke, doctors often need to check if an irregular heartbeat called atrial fibrillation caused it — because this affects how you'll be treated. This study is testing a new device called ECG247, a small wireless patch that sticks to your chest and continuously monitors your heart rhythm for up to two weeks. The patch is water-resistant, connects to a smartphone app, and sends data to doctors automatically, which may catch heart rhythm problems that standard hospital monitors miss.
Atrial fibrillation often comes and goes unpredictably, so it's frequently missed by standard heart monitors that only work for a day or two. Better detection could help doctors prevent future strokes and give you the right treatment sooner.
You likely qualify if…
You likely don't qualify if…
If you are selected for the study, you'll be randomly assigned to wear either the ECG247 patch or receive standard heart monitoring. If you get the patch, it will be applied to your chest in the hospital and you'll wear it continuously for up to 14 days — both during your hospital stay and at home after discharge. The patch is wireless and waterproof, so you can shower and move around normally. You'll use a smartphone app to stay connected with the study team, and doctors will review any detected heart rhythm problems. The whole study lasts about two weeks, and you'll have follow-up visits to check your progress.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Norway